Health & Beauty

The University of Hong Kong-Shenzhen Hospital ("HKU-Shenzhen Hospital") recently stated that the hospital introduced two new tumor drugs, "Entratinib" and "Lorlatinib" through the "Hong Kong-Macao Medicine and Machinery Access" policy. At present, two new tumor drugs have arrived and are about to be put into clinical use, which will provide alternative treatments for patients with refractory and specific gene mutation cancer types.

It is reported that this is the first batch of new oral anti-cancer drugs introduced since the implementation of the "Hong Kong-Macao Medicine Machinery" policy in Shenzhen Hospital of Hong Kong University. approved drugs for clinical use. Up to now, a total of 9 drugs and 2 devices have been or will be put into clinical use in HKU-Shenzhen Hospital.

According to reports, entrectinib and lorlatinib are both newly approved anticancer drugs in the world. Entrectinib is the third pan-tumor anticancer drug in the world for the treatment of adult and pediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors that have progressed or not after initial therapy Solid tumor patients with standard treatment, as well as ROS1-positive non-small cell lung cancer (NSCLC) patients, regardless of tumor types, including pancreas, thyroid, salivary gland, breast, colorectal and lung cancer.

Lorlatinib is currently the only approved third-generation anaplastic lymphoma kinase ALK (Anaplastic Lymphoma Kinase) inhibitor, which is suitable for patients with ALK-positive advanced non-small cell lung cancer. The penetration ability is strong, and it is expected to prolong the survival period of such patients.

Li Yongmei, Deputy Dean of Medical and Teaching and Director of Comprehensive Cancer Treatment Center of HKU Shenzhen Hospital, introduced that entrectinib is a representative drug for precision tumor treatment, which enables tumor treatment to move from traditional "site therapy" to "gene therapy"; The introduction of lorlatinib has brought new hope for some patients who have been sentenced to "death penalty" in the past.

Previously, the first drug "Anti-D globulin injection" and the first drug "Magnetic Controllable Prolongation Great" of "Hong Kong-Macao Yaojitong" were put into use in Shenzhen Hospital of Hong Kong University. Ms. Yang, a pregnant woman who originally planned to go to Macau for injection, was injected with "Anti-D Immune Globulin Injection" at the Shenzhen Hospital of Hong Kong University, becoming the first patient to benefit from the "Hong Kong-Macao Pharmaceutical Machinery" policy. "Magnetically Controllable Lengthening Titanium Rod" Chief Surgeon Zhang Wenzhi and his team successfully performed surgery on a 9-year-old child.

It is understood that as of August 15, 165 "anti-D immune globulin injection" (149 person-times) have been used, and "magnetic controllable extension titanium rod" has also benefited 3 patients, and there are currently no adverse reactions.

In addition, the "Hong Kong-Macao Pharmaceutical Machinery" policy has approved nine drugs and two medical devices, including new drugs for the treatment of hematological tumors, severe chronic obstructive pulmonary disease, epilepsy and other diseases. Some of the medicines have already arrived at the Hong Kong University Shenzhen Hospital and will be put into use in the near future.